. 2015 Jul 2;6(1):2. doi: 10.1186/s12645-015-0010-5

Table 3.

Summary of ongoing or unpublished clinical trials utilising DNA vaccines for prostate cancer

Vaccine/ targeted antigen	Phase trial/ estimated enrolment	Delivery route	Primary objectives	Ref
PAP: Sipuleucel-T with or without pTVG-HP (100 μg)/ rhGM-CSF (200 μg)	Phase II (NCT01706458) N = 30	i.d.	PAP-specific Immunological response	[113]
PAP: rhGM-CSF (200 μg) with or without pTVG-HP (100 μg)	Phase II (NCT01341652) N = 56	i.d.	Metastasis-free survival	[114]
PSA: PROSTVAC with or without GM-CSF (100 μg)	Phase III (NCT01322490) N = 1200	s.c.	Overall Survival	[77]
PSA: Flutamide with or without PROSTVAC	Phase II (NCT00450463) N = 53	s.c.	Time to Treatment Failure	[115]
PSA: Adenovirus/PSA (1X10⁸ pfu in gelfoam)	Phase II (NCT00583024) N = 66	s.c.	PSA-DT Response	[76]
PSA: Adenovirus/PSA (1X10⁸ pfu in gelfoam) with or without ADT	Phase II (NCT00583752) N = 70	s.c.	PSA-DT Response	[116]